Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (461-470 of 471) with videos related to

Pageof 48
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Inflammatory Bowel Diseases|June 5, 2024
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic ReviewKatherine Falloon, Zahra Dossaji, Pooja Mude, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative ColitisParambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
The American Journal of Gastroenterology|October 3, 2022
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS ConsortiumAmanda M Johnson, Maria Barsky, Waseem Ahmed, et al.
Pageof 48

Showing results (461-470 of 471) with videos related to

Sort By:
Pageof 48
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Inflammatory Bowel Diseases|June 5, 2024
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic ReviewKatherine Falloon, Zahra Dossaji, Pooja Mude, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2020
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative ColitisParambir S Dulai, Siddharth Singh, Niels Vande Casteele, et al.
The American Journal of Gastroenterology|October 3, 2022
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS ConsortiumAmanda M Johnson, Maria Barsky, Waseem Ahmed, et al.
Pageof 48